SNRPB was found to be upregulated in ovarian cancer cells, promoted tumor growth, supported canonical BRCA2 splicing, and suppressed aberrant exon 3 skipping, thereby affecting the response to cisplatin. Here, SNRPB is linked to ovarian carcinoma.